血清β_(2)-微球蛋白、CRP联合骨髓涂片检测多发性骨髓瘤的应用  

Application of Serum β_(2)-microglobulin and CRP Combined with Bone Marrow Smear for Detection of Multiple Myeloma

作　　者：彭丽君 周仲煜[2] 杨柳华[1] 季沈杰[1] PENG Lijun;ZHOU Zhongyu;YANG Liuhua;JI Shenjie(Department of Laboratory,Qidong People's Hospital,Qidong,Jiangsu Province,226200 China;Department of Laboratory,Taiyuan People's Hospital,Taiyuan,Shanxi Province,030001 China)

机构地区：[1]江苏省启东市人民医院检验科,江苏启东226200 [2]山西省太原市人民医院检验科,山西太原030001

出　　处：《系统医学》2022年第20期29-33,共5页Systems Medicine

摘　　要：目的分析血清β_(2)-微球蛋白、C-反应蛋白(C-reactive protein,CRP)联合骨髓涂片对多发性骨髓瘤的诊断价值。方法选取2019年2月—2022年2月江苏省启东市人民医院就诊的90例多发性骨髓瘤疑似患者为研究对象,对患者血清β_(2)-微球蛋白、CRP水平进行检测,所有患者均行骨髓涂片检测,分析联合检测与单一指标对多发性骨髓瘤的检出率,对比诊断效能和不同分期患者实验室指标水平。结果血清β_(2)-微球蛋白、CRP联合骨髓涂片对多发性骨髓瘤的检出率为97.06%,高于单一指标,差异有统计学意义(χ^(2)=7.962、9.066、5.849,P<0.05);联合诊断多发性骨髓瘤的敏感性、特异性、准确性、阳性预测值和阴性预测值分别为97.06%、95.45%、96.67%、98.57%、91.30%,高于单一指标诊断效能,差异有统计学意义(P<0.05);Ⅲ期患者血清β_(2)-微球蛋白、CRP水平明显高于Ⅰ期、Ⅱ期患者,差异有统计学意义(P<0.05)。结论联合应用血清β_(2)-微球蛋白、CRP和骨髓涂片可准确诊断多发性骨髓瘤,也可用于疾病分期评估,有应用价值。Objective To analyze the diagnostic value of serumβ_(2)-microglobulin and C-reactive protein(C-reactive protein,CRP)combined with bone marrow smear for multiple myeloma.Methods 90 patients with suspected multiple myeloma who attended the People′s Hospital of Qidong City,Jiangsu Province from February 2019 to February 2022were selected as the research object.Serumβ_(2)-microglobulin and CRP levels were measured,and all patients underwent bone marrow smear testing to analyze the detection rate of multiple myeloma by combined testing versus single index.The diagnostic efficacy and the levels of laboratory indicators in patients with different stages were compared.Results The detection rate of serumβ_(2)-microglobulin and CRP combined with bone marrow smear for multiple myeloma was 97.06%,which was higher than that of single indexes,and the difference was statistically significant(χ^(2)=7.962,9.066,5.849,P<0.05);the sensitivity,specificity,accuracy,positive predictive value and negative predictive value of the combined diagnosis of multiple myeloma were 97.06%,95.45%,96.67%,98.57%and 91.30%,respectively,which were higher than the diagnostic efficacy of single index,and the difference was statistically significant(P<0.05);the serumβ_(2)-microglobulin and CRP levels of stageⅢpatients were significantly higher than those of stage I andⅡpatients,and the difference was statistically significant(P<0.05).Conclusion The combined application of serumβ_(2)-microglobulin,CRP and bone marrow smear can accurately diagnose multiple myeloma and also be used for disease stage assessment,which has application value.

关 键 词：β_(2)-微球蛋白 C反应蛋白 骨髓涂片 多发性骨髓瘤 

分 类 号：R521[医药卫生—内科学]